Jefferies Keeps a Hold Rating on Stryker

By Carrie Williams

In a report released yesterday, Raj Denhoy from Jefferies reiterated a Hold rating on Stryker (NYSE: SYK), with a price target of $132. The company’s shares closed yesterday at $138.81.

According to, Denhoy is a top 100 analyst with an average return of 17.7% and a 76.1% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Stryker is Hold and the average price target is $140.10, representing a 0.9% upside.

In a report issued on June 19, Oppenheimer also reiterated a Hold rating on the stock.

Stryker’s market cap is currently $51.91B and has a P/E ratio of 31.16. The company has a book value ratio of 5.3499.

Based on the recent corporate insider activity of 118 insiders, corporate insider sentiment is neutral on the stock. Last month, Roch Doliveux, a Director at SYK bought 46 shares for a total of $6,240.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stryker Corp. is engaged in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems.